On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Eleven Biotherapeutics, Inc.’s (EBIO) Acquisition of Viventia Bio Creates Targeted Protein Therapeutics Oncology Company

Company: Eleven Biotherapeutics, Inc. (EBIO)
Category: News

Through a share purchase agreement, Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) has acquired Viventia Bio, Inc., creating a single entity focused on the development of novel treatments in areas of oncology with significant unmet need. In addition to other drug candidates, Eleven’s pipeline now includes Viventias’ two lead product candidates: Vicinium, in a phase 3 clinical trial for high-grade non-muscle invasive bladder cancer (NMIBC), with topline data expected in the first half of 2018; and Proxinium, expected to enter phase 2 development in early 2017 for the treatment of late-stage squamous cell carcinoma of the head and neck.

To view the full press release, visit: http://nnw.fm/pSp1C

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on the Company’s targeted protein therapeutics (TPTs) platform. The Company’s TPTs genetically combine antibody-based fragments with protein immunotoxin
payloads to create a single protein molecule through the Company’s proprietary one-step manufacturing process. The Company believes its TPTs can potentially offer significant advantages in treating cancer versus existing antibody drug conjugate technologies. The Company’s approach to drug design creates TPTs that it believes facilitate effective tumor targeting with cancer cell-killing properties unique to protein payloads versus small molecules. The ability of TPTs cancer cell-killing properties to promote an anti-tumor immune response suggest that TPTs will potentially combine well with immune oncology drugs. TPTs fusion protein construction provides enhanced linker stability and an efficient and cost effective manufacturing process. For more information please refer to the Company’s website www.elevenbio.com.

About NetworkNewsBreak

NetworkNewsBreak is a rapid summary of a press release that caught the attention of NetworkNewsWire (NNW). NNW provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit https://www.NetworkNewsWire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Contact us: 212.418.1217